Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome plus fruquintinib for ≥ second-line recurrent colorectal cancer
ChiCTR2400088697Phase 2Not yet recruiting
- Sponsor
- Arion Cancer Hospital
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan and fruquintinib in colorectal cancer (CRC), sponsored by Arion Cancer Hospital. Primary endpoint: Disease control rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecanfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400088697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088697.